AVITA Medical announced a 10‑year agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA) that values the contract at up to $25.5 million and guarantees delivery of 3,000 RECELL® spray‑on skin units over the term. The deal establishes a strategic reserve of the device for use in mass‑casualty burn incidents and provides AVITA with a predictable, government‑backed revenue stream.
Prior to the BARDA agreement, AVITA reported full‑year 2025 revenue of $71.6 million and a net loss of $48.6 million. The company also secured a $60 million credit facility in January 2026 to support operations and growth initiatives. The new contract adds a steady cash flow that can help offset the company’s historical losses and fund platform expansion and cost‑reduction programs.
Strategically, the partnership expands AVITA’s commercial footprint beyond its core burn‑center customer base. By ensuring national access to RECELL® for mass‑casualty events, AVITA positions itself as a key player in public‑health emergency preparedness, aligning with BARDA’s mission to stockpile medical countermeasures for CBRN threats.
The guaranteed 3,000 units and the up‑to‑$25.5 million value translate into an expected $3.97 million in access‑maintenance and readiness fees over the decade. This predictable revenue stream improves AVITA’s cash‑flow profile, supports ongoing platform development, and enhances the company’s ability to manage working‑capital needs amid its current loss position.
Overall, the BARDA agreement represents a significant milestone for AVITA, providing both strategic positioning in national preparedness and a tangible, long‑term revenue source that can help stabilize the company’s financial trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.